(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026158 A1

(51) International Patent Classification[7]: C07D 405/12, 239/48, 405/14, 413/14, 417/14, 403/12, A61K 31/506

(21) International Application Number:
PCT/EP2004/010348

(22) International Filing Date:
15 September 2004 (15.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0321710.6	16 September 2003 (16.09.2003)	GB
0414440.8	28 June 2004 (28.06.2004)	GB

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BAENTELI, Rolf** [CH/CH]; Davidsbodenstrasse 64, CH-4056 Basel (CH). **BERNHARD, Marie, Claude** [FR/FR]; Rue de Kiffis 48, F-68480 Wolschwiller (FR). **BUEHLMAYER, Peter** [CH/CH]; Hangstrasse 18, CH-4144 Arlesheim (CH). **COOKE, Nigel, Graham** [GB/CH]; Tichelengraben 13, CH-4104 Oberwil (CH). **DUTHALER, Rudolf** [CH/CH]; Girenhaldenweg 17, CH-4126 Bettingen (CH). **HINTERDING, Klaus** [DE/DE]; Am Oelbachgraben 6, 79599 Wittlingen (DE). **THOMA, Gebhard** [DE/DE]; Talweg 32, 79540 Lörrach (DE). **VAN EIS, Maurice** [NL/FR]; 26, Rue de Wentzwiller, F-68220 Buschwiller (FR). **VON MATT, Anette** [DE/CH]; Fichtlirain 38, CH-4105 Biel-Benken (CH). **WALLISER, Louis** [FR/FR]; Rue de Hagenthal 26, F-68220 Leymen (FR). **ZENKE, Gerhard** [DE/DE]; Adolf-Glattacker-Strasse 8, 79618 Rheinfelden (DE).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/026158 A1

(54) Title: 2,4 DI (HETERO) -ARYLAMINO-PYRIMIDINE DERIVATIVES AS ZAP-70 AND/OR SYK INHIBITORS



(1)

(57) Abstract: Disclosed are pyrimidine derivatives of formula (I); wherein R^0, R^1, R^3 to R^9, and Z have a signification as indicated in claim 1, which have ZAP-70 and/or Syk inhibitory activities.